TLP
Tri Locum Partners Portfolio holdings
AUM
$330M
This Quarter Return
+31.35%
1 Year Return
+35.44%
3 Year Return
+388.28%
5 Year Return
–
10 Year Return
–
AUM
$249M
AUM Growth
+$249M
(+16%)
Cap. Flow
+$27.8M
Cap. Flow
% of AUM
11.14%
Top 10 Holdings %
Top 10 Hldgs %
63.51%
Holding
54
New
28
Increased
6
Reduced
4
Closed
14
Top Buys
| 1 |
AbbVie
ABBV
|
$24.4M |
| 2 |
Eli Lilly
LLY
|
$21.7M |
| 3 |
argenx
ARGX
|
$16.9M |
| 4 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$15.3M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$15M |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$28.6M |
| 2 |
Baxter International
BAX
|
$25.1M |
| 3 |
WBA
Walgreens Boots Alliance
WBA
|
$14.7M |
| 4 |
Merck
MRK
|
$13.7M |
| 5 |
Medtronic
MDT
|
$13M |
Sector Composition
| 1 | Healthcare | 88.73% |
| 2 | Consumer Staples | 4.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
AbbVie
ABBV
$372B
| $24.4M | 9.59% | +179,950 | New | +$24.4M |
|
|
2
Eli Lilly
LLY
$657B
| $21.7M | 8.54% | +78,528 | New | +$21.7M |
|
3
Edwards Lifesciences
EW
$47.8B
| $19.1M | 7.52% | 147,396 +24,516 | +20% | +$3.18M |
|
|
4
argenx
ARGX
$43.6B
| $16.9M | 6.67% | +48,347 | New | +$16.9M |
|
|
CCXI
5
DELISTED
ChemoCentryx, Inc.
CCXI
| $15.9M | 6.25% | 436,300 +420,255 | +2,619% | +$15.3M |
|
|
6
Apellis Pharmaceuticals
APLS
$3.48B
| $15M | 5.92% | +318,269 | New | +$15M |
|
7
Kezar Life Sciences
KZR
$28.9M
| $12.2M | 4.82% | +732,515 | New | +$12.2M |
|
8
The Beauty Health Co
SKIN
$264M
| $12.2M | 4.82% | 506,280 +1,674 | +0.3% | +$40.4K |
|
9
Protagonist Therapeutics
PTGX
$3.67B
| $10.7M | 4.23% | +313,929 | New | +$10.7M |
|
10
Adicet Bio
ACET
$59.9M
| $10.2M | 4.02% | +583,402 | New | +$10.2M |
|
11
United Therapeutics
UTHR
$13.8B
| $9.92M | 3.91% | 45,904 +13,053 | +40% | +$2.82M |
|
|
INBX
12
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $9.31M | 3.66% | +213,174 | New | +$9.31M |
|
|
SGEN
13
DELISTED
Seagen Inc. Common Stock
SGEN
| $9.27M | 3.65% | 59,940 -36,367 | -38% | -$5.62M |
|
14
Fate Therapeutics
FATE
$120M
| $8.31M | 3.27% | +142,032 | New | +$8.31M |
|
|
BLU
15
DELISTED
BELLUS Health Inc.
BLU
| $7.86M | 3.09% | 975,933 +2,936 | +0.3% | +$23.6K |
|
16
Evolent Health
EVH
$1.12B
| $6.23M | 2.45% | +225,097 | New | +$6.23M |
|
17
Stevanato
STVN
$6.28B
| $5.09M | 2% | +226,700 | New | +$5.09M |
|
18
Legend Biotech
LEGN
$6.41B
| $4.19M | 1.65% | 89,840 -78,627 | -47% | -$3.66M |
|
19
X4 Pharmaceuticals
XFOR
$84.2M
| $3.62M | 1.42% | +1,578,947 | New | +$3.62M |
|
|
SNCE
20
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $3.38M | 1.33% | 271,159 +7,870 | +3% | +$98.1K |
|
|
BHVN
21
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $3.36M | 1.32% | +24,346 | New | +$3.36M |
|
|
CTLT
22
DELISTED
CATALENT, INC.
CTLT
| $3.03M | 1.19% | +23,700 | New | +$3.03M |
|
23
Zentalis Pharmaceuticals
ZNTL
$122M
| $1.99M | 0.78% | +23,632 | New | +$1.99M |
|
|
ABMD
24
DELISTED
Abiomed Inc
ABMD
| $1.86M | 0.73% | +5,169 | New | +$1.86M |
|
25
RAPT Therapeutics
RAPT
$188M
| $1.77M | 0.7% | +48,141 | New | +$1.77M |
|